The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 M...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.975578/full |
| _version_ | 1818030199874256896 |
|---|---|
| author | Rong He Fei Lin Fei Lin Bin Yu Jingyue Qiu Lingli Zheng |
| author_facet | Rong He Fei Lin Fei Lin Bin Yu Jingyue Qiu Lingli Zheng |
| author_sort | Rong He |
| collection | DOAJ |
| description | Background: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 March 2022. Only randomized controlled trials (RCTs) that evaluated delafloxacin and comparator antibiotics for treating acute bacterial infections in adult patients were included. The clinical cure rate and microbiological eradication rate at the posttreatment evaluation, while the secondary outcomes included the risk of adverse events (AEs).Results: In total, six randomized controlled trials (RCTs) involving 3,019 patients with acute bacterial infection were included. There were no significant differences in the clinical cure rate between delafloxacin and comparators (OR = 1.06%, 95% CI = 0.89–1.26, I2 = 0%). Overall, the results showed that delafloxacin had a microbiological eradication rate (documented and presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94–1.88, I2 = 0%) in the pooled analysis of the six studies. Any treatment-emergent adverse events (TEAEs) did not show significant differences between delafloxacin and the comparators (OR = 0.93%, 95% CI = 0.80–1.08, I2 = 75%). Serious adverse events (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% CI = 0.67–1.32, I2 = 0%). The results of gastrointestinal disorders were (OR = 1.26%, 95% CI = 1.01–1.56, I2 = 89%), and nausea, vomiting, and diarrhea were (OR = 0.77%, 95% CI = 0.45–1.34, I2 = 79%), (OR = 1.00%, 95% CI = 0.74–1.36, I2 = 72%), and (OR = 2.10%, 95% CI = 1.70–2.96, I2 = 0%), respectively. The results showed that there was no significant difference in the incidence of nausea and vomiting between delafloxacin and the comparator, but the incidence of diarrhea was higher. The analysis of neurological disorders indicated that the incidence of nervous system disorders was lower in the delafloxacin group (OR = 0.71%, 95% CI = 0.50–1.01, I2 = 52%).Conclusion: The clinical efficacy, microbiological eradication rate and the incidence of AEs of delafloxacin in the treatment of acute bacterial infections were similar to those of the comparators, as an alternative therapeutic agent. |
| first_indexed | 2024-12-10T05:31:48Z |
| format | Article |
| id | doaj.art-67ee46744c54407ca203854d3beb04d5 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-10T05:31:48Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-67ee46744c54407ca203854d3beb04d52022-12-22T02:00:31ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-09-011310.3389/fphar.2022.975578975578The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trialsRong He0Fei Lin1Fei Lin2Bin Yu3Jingyue Qiu4Lingli Zheng5Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaSichuan Province College Key Laboratory of Structure-Specific Small Molecule Drugs, Chengdu Medical College, Chengdu, ChinaDepartment of Pharmacy, Mianyang Central Hospital, Mianyang, ChinaDepartment of Pharmacy, PLA Strategic Support Force Medical Center, Beijing, ChinaDepartment of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaBackground: This study aims to assess the clinical efficacy and adverse events of delafloxacin for the treatment of acute bacterial infections in adult patients through meta-analysis.Methods: The PubMed, Embase, Cochrane library, Web of Science, and Clinical trails databases were searched up to 26 March 2022. Only randomized controlled trials (RCTs) that evaluated delafloxacin and comparator antibiotics for treating acute bacterial infections in adult patients were included. The clinical cure rate and microbiological eradication rate at the posttreatment evaluation, while the secondary outcomes included the risk of adverse events (AEs).Results: In total, six randomized controlled trials (RCTs) involving 3,019 patients with acute bacterial infection were included. There were no significant differences in the clinical cure rate between delafloxacin and comparators (OR = 1.06%, 95% CI = 0.89–1.26, I2 = 0%). Overall, the results showed that delafloxacin had a microbiological eradication rate (documented and presumed) similar to the comparators (OR = 1.33%, 95% CI = 0.94–1.88, I2 = 0%) in the pooled analysis of the six studies. Any treatment-emergent adverse events (TEAEs) did not show significant differences between delafloxacin and the comparators (OR = 0.93%, 95% CI = 0.80–1.08, I2 = 75%). Serious adverse events (SAEs) did not differ between the delafloxacin and comparators (OR = 0.94%, 95% CI = 0.67–1.32, I2 = 0%). The results of gastrointestinal disorders were (OR = 1.26%, 95% CI = 1.01–1.56, I2 = 89%), and nausea, vomiting, and diarrhea were (OR = 0.77%, 95% CI = 0.45–1.34, I2 = 79%), (OR = 1.00%, 95% CI = 0.74–1.36, I2 = 72%), and (OR = 2.10%, 95% CI = 1.70–2.96, I2 = 0%), respectively. The results showed that there was no significant difference in the incidence of nausea and vomiting between delafloxacin and the comparator, but the incidence of diarrhea was higher. The analysis of neurological disorders indicated that the incidence of nervous system disorders was lower in the delafloxacin group (OR = 0.71%, 95% CI = 0.50–1.01, I2 = 52%).Conclusion: The clinical efficacy, microbiological eradication rate and the incidence of AEs of delafloxacin in the treatment of acute bacterial infections were similar to those of the comparators, as an alternative therapeutic agent.https://www.frontiersin.org/articles/10.3389/fphar.2022.975578/fulldelafloxacinacute bacterial infectionsS. aureumeta analysisefficacy |
| spellingShingle | Rong He Fei Lin Fei Lin Bin Yu Jingyue Qiu Lingli Zheng The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials Frontiers in Pharmacology delafloxacin acute bacterial infections S. aureu meta analysis efficacy |
| title | The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials |
| title_full | The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials |
| title_fullStr | The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials |
| title_full_unstemmed | The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials |
| title_short | The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials |
| title_sort | efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections a systematic review and meta analysis of randomized controlled trials |
| topic | delafloxacin acute bacterial infections S. aureu meta analysis efficacy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.975578/full |
| work_keys_str_mv | AT ronghe theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT binyu theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jingyueqiu theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT linglizheng theefficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT ronghe efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT feilin efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT binyu efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT jingyueqiu efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials AT linglizheng efficacyandadverseeventsofdelafloxacininthetreatmentofacutebacterialinfectionsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials |